Luye Pharma Group Ltd. (LYPHF)
Market Closed
17 Jul, 18:40
$
0. 27
-0.05
-14.7996%
$
1.31B Market Cap
- P/E Ratio
- Div Yield
2,500 Volume
- Eps
$ 0.32
Previous Close Want to track LYPHF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
LYPHF closed yesterday lower at $0.27, a decrease of -14.7996% from Thursday's close, completing a monthly decrease of -17.6327% or -$0.06. Over the past 12 months, LYPHF stock lost -27.027%.
LYPHF is not paying dividends to its shareholders.
The last earnings report, released on Apr 01, 2026, missed the consensus estimates by -0.0114%. On average, the company has fell short of earnings expectations by -0.0057%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
Luye Pharma Group Ltd. (LYPHF) FAQ
What is the stock price today?
The current price is $0.27.
On which exchange is it traded?
Luye Pharma Group Ltd. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is LYPHF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.31B.
Has Luye Pharma Group Ltd. ever had a stock split?
No, there has never been a stock split.
Luye Pharma Group Ltd. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mr. Dian Bo Liu CEO | OTC PINK Exchange | BMG570071099 ISIN |
| DE Country | 5,115 Employees | - Last Dividend | - Last Split | - IPO Date |
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; and Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; research and development of antibody drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
Contact Information
Address: No. 15 Chuang Ye Road, Yantai, China, 264003
Phone: -
Website: https://www.luye.cn
